Business Wire

POLYMATERIA

15.6.2021 09:02:06 CEST | Business Wire | Press release

Share
Polymateria Awarded as Technology Pioneer by World Economic Forum

Polymateria, the London-based British tech company that last year produced the world’s first fully recyclable and biodegradable plastic, was selected among hundreds of candidates as one of the World Economic Forum’s “Technology Pioneers”. Polymateria came through Imperial College London’s incubator system and counts a diverse portfolio of customers and partners from Indorama Ventures, to Hollywood Actress Robin Wright, purposeful auto racing Extreme E, Rolling Loud Festivals, DAZN Sports TV network and the Indian Government.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210615005173/en/

The World Economic Forum’s Technology Pioneers are early to growth-stage companies from around the world that are involved in the use of new technologies and innovation that are poised to have a significant impact on business and society.

With their selection as Technology Pioneer, CEO Niall Dunne of Polymateria will be invited to participate at World Economic Forum activities, events and discussions throughout the year. Polymateria will also contribute to Forum initiatives over the next two years, working with global leaders to help address key industry and societal issues.

“We’re excited to welcome Polymateria to our 2021 cohort of Technology Pioneers,” says Susan Nesbitt, Head of the Global Innovators Community, World Economic Forum. “Polymateria and its fellow pioneers are developing technologies that can help society solve some of its most pressing issues. We look forward to their contribution to the World Economic Forum in its commitment to improving the state of the world.”

“It’s great to be acknowledged as a tech pioneer by the World Economic Forum”, said Polymateria’s CEO, Niall Dunne. “Since we were founded we’ve been obsessed with the scientific credibility and scale needed to solve the fugitive plastic crisis. This obsession has yielded a number of science based break throughs supported by & validated through new world leading standards specifically for the materials that are most likely to wind up in nature. It’s also clear that the ultimate beach head for innovation in this area is working with the next generation of consumers to empower them to champion the change needed from industry and other stakeholders and this will be our top priority in working within the WEF community.”

For the first time in the community’s history, over 30% of the cohort are led by women. The firms also come from regions all around the world, extending their community far beyond Silicon Valley. This year’s cohort includes start-ups from 26 countries, with UAE, El Salvador, Ethiopia and Zimbabwe represented for the first time.

The diversity of these companies extends to their innovations as well. 2021 Tech Pioneer firms are shaping the future by advancing technologies such as AI, IoT, robotics, blockchain, biotechnology and many more. The full list of Technology Pioneers can be found here .

Technology Pioneers have been selected based on the community’s selection criteria, which includes innovation, impact and leadership as well as the company’s relevance with the World Economic Forum’s Platforms .

All info on this year’s Technology Pioneers can be found here: http://wef.ch/techpioneers21

More information on past winners, information on the community and the application link can be found here .

About Polymateria :

Polymateria’s mission is to advance science to help nature deal with the plastic pollution crisis. Born from, and now based at, Imperial College London, they are the first company in the world to prove scientifically that you can take the most likely sources of fugitive or littered plastics and return them to nature without creating microplastics, harming the natural environment or interfering with recycling streams at scale.

The British Standards Institutions’s new BSI PAS 9017 standard ensures claims of biodegradability in the open environment can be properly verified for the first time according to independent pass/fail criteria. The Standard and Polymateria’s technology were recently featured in National Geographic magazine: https://www.nationalgeographic.co.uk/environment-and-conservation/2020/11/new-self-destructing-plastic-has-helped-define-a-new-british

Polymateria has partnership with some of the biggest technical partners in the world such as Clariant (now Avient, see https://www.clariant.com/en/Corporate/News/2019/10/Clariant-and-Polymateria-launch-partnership-to-bring-new-Biotransformation-technology-to-market-in-S ) and Indorama Ventures for non-woven applications (see https://www.innovationintextiles.com/indorama-companies-prepare-for-biotransformation/ ). Additionally the UK Govt included them as part of new trade with India (https://www.gov.uk/government/news/prime-minister-announces-1-billion-of-new-uk-india-trade ).

In its most recent collaboration, Polymateria will be providing Extreme E, an all-electric off-road racing series, with plastic cups and flexible film that in the unlikely event of escaping into the natural environment will safely and quickly biodegrade leaving no toxins and microplastics behind: https://www.extreme-e.com/en/news/214_Extreme-E-joins-forces-with-Polymateria-to-tackle-global-plastic-pollution.html

Pour Les Femmes, the ethical brand founded by actor/activitist Robin Wright and designer Karen Fowler, is the first apparel brand to introduce Polyamteria’s technology into its packaging: https://pourlesfemmes.com/blogs/pillowtalk/whats-the-future-of-plastic-waste-robin-wright-niall-dunne

The company is proud to be a founding signatory of HRH The Prince of Wales’ Terra Carta (Earth Charter) established under the Sustainable Markets Initiative.

About World Economic Forum :

The World Economic Forum, committed to improving the state of the world, is the International Organization for Public-Private Cooperation. The Forum engages the foremost political, business and other leaders of society to shape global, regional and industry agendas. (www.weforum.org ).

About the Technology Pioneers:

The World Economic Forum believes that innovation is critical to the future well-being of society and to driving economic growth. Launched in 2000, the Technology Pioneer community is composed of early to growth-stage companies from around the world that are involved in the design, development and deployment of new technologies and innovations, and are poised to have a significant impact on business and society.

The World Economic Forum provides the Technology Pioneers community with a platform to engage with the public- and private-sector leaders and to contribute new solutions to overcome the current crisis and build future resiliency.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye